A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer.
about
Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to nePegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.
P2860
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A phase II study of dose-dense ...... stage II, IIIA breast cancer.
@ast
A phase II study of dose-dense ...... stage II, IIIA breast cancer.
@en
type
label
A phase II study of dose-dense ...... stage II, IIIA breast cancer.
@ast
A phase II study of dose-dense ...... stage II, IIIA breast cancer.
@en
prefLabel
A phase II study of dose-dense ...... stage II, IIIA breast cancer.
@ast
A phase II study of dose-dense ...... stage II, IIIA breast cancer.
@en
P2093
P356
P1433
P1476
A phase II study of dose-dense ...... stage II, IIIA breast cancer.
@en
P2093
A Grassadonia
A I Rispoli
C Ficorella
D Angelucci
E Cianchetti
E Ricevuto
M De Tursi
P304
P356
10.1093/ANNONC/MDM076
P577
2007-03-17T00:00:00Z